A diversified portfolio
Turning hope into impact, we're advancing novel and targeted medicines to address the needs of every patient. With a focus on breakthrough science in Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology Conditions, Vaccines & Immune Therapy and Rare Disease. Our mission is to transform lives, improve outcomes and enhance quality of life through prevention and more effective treatments.
Our mission & Our vision for patients is to deliver the healthcare experience and outcomes that people care about most so they can enjoy their lives. Everything we do is aimed at enhancing the lives of people with disease and illness.
Sustainable impact in healthcare: building a healthy future for people, society and the planet
We take a holistic approach to the delivery of life-changing medicines, embedding sustainability into everything we do. We know that taking action to drive sustainability is fundamental, not only to the health of the planet, but to a healthy society and people.
Empowering people
We value our people as our greatest asset, understanding the potential unlocked by a talented and diverse team united by a shared belief in the power of science.
Over 220 talented employees across AstraZeneca BeLux working in an environment of entrepreneurship and trust.
Giving back to society thanks to our “AZ Foundation”
Since 1994, we've allocated over €5 million through our researcher prizes, supporting impactful research initiatives in Belgium.
Our dedicated employees actively engage in projects, embodying our commitment to making a positive impact in the community.
*The AstraZeneca Foundation was established in January 1994 by AstraZeneca BeLux under an independent structure.
Protecting our planet
Embarking on the creation of our global "AZ Forest", 
we planted 1.5 hectares of trees near our office in 2023 to contribute to a sustainable and local impact.
By 2025, we're committed to achieving emission elimination from our operations without relying on offset schemes. Our strategy includes doubling Energy Productivity and eliminating E-gaz Emissions on our sites, transitioning to 100% renewable energy, and establishing a fully electric vehicle fleet.
Next generation AZ inhalers will use a new propellant with significant (99%) lower climate impact.
NS ID XL-3973-Revision date 12/2023-WEB Local code 2150